title: Different recovery patterns of mouse haemopoietic stem cells in response to cytotoxic agents.
abstract: The response and subsequent recovery of mouse haemopoietic progenitor cells (spleen colony forming cells and agar colony forming cells) has been studied following two cytotoxic agents. Busulphan was administered to normal mice and vinblastine to mice where the progenitor cell proliferation rate had been increased by a period of continuous gamma-irradiation. With both these agents there is a difference between the response of the spleen colony forming cells and the agar colony forming cells during the first five days. They then recover together, but much more slowly after fusulphan than after vinblastine even though their proliferation rate is increased. The rate of progenitor cell recovery after busulphan is increased if the progenitor cells are depleted further by vinblastine. However, methotrexate, which severely depletes the peripheral blood count and bone marrow cellularity but not the progenitor cells, has no effect on the recovery following busulphan. These results suggest that following cytotoxic agents the agar colony forming cells ("committed" stem cells) are not self-maintaining but are dependent on a supply of cells from the pluripotential spleen colony forming cells. In addition it appears that the depletion of the progenitor cells of the bone marrow and not the depletion of the maturing cells, provides a stimulus for stem cell recovery.
mesh_terms: D000818:Animals; D001772:Blood Cell Count; D001854:Bone Marrow Cells; D002066:Busulfan / Q000494:pharmacology*; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D004920:Erythropoiesis / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D008727:Methotrexate / Q000494:pharmacology; D051379:Mice; D013154:Spleen / Q000166:cytology; D013156:Splenectomy; D014747:Vinblastine / Q000494:pharmacology*
chemical_list: D014747:Vinblastine; D002066:Busulfan; D008727:Methotrexate